AbbVie and Roche combo comes good in CLL

A Phase III trial combining AbbVie’s Venclexta/Venclyxto (venetoclax) and Roche’s MabThera/Rituxan (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), has met its primary endpoint.

The MURANO study showed that people with previously treated CLL who were given this combination lived longer without their disease worsening compared to bendamustine plus MabThera/Rituxan.